

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/051,956	01/16/2002	Larry Mobraaten	03887,0002.NPUS00	1758
27194	7590 11/05/2003		EXAM	INER
HOWREY	SIMON ARNOLD &	SHUKLA, RAM R		
BOX 34				
301 RAVEN	SWOOD AVE.		ART UNIT	PAPER NUMBER
MENLO PA	RK, CA 94025		1632	

DATE MAILED: 11/05/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
Office Action Summary	10/051,956	MOBRAATEN ET AL.
	Examiner Ram R. Shukla	Art Unit
Th MAILING DATE of this communication app		
Period for Reply		•
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a represent the statutory minimum of thirty within the statutory minimum of thirty will apply and will expire SIX (6) MONTI cause the application to become ABA	oly be timely filed (30) days will be considered timely. HS from the mailing date of this communication. NDONED (35 U.S.C. § 133).
1) Responsive to communication(s) filed on	·	
2a)☐ This action is FINAL . 2b)☐ Thi	is action is non-final.	
3) Since this application is in condition for alloward closed in accordance with the practice under		
Disposition of Claims		
4) Claim(s) 1-28 is/are pending in the application		
4a) Of the above claim(s) is/are withdray 5) Claim(s) is/are allowed.	wir from Consideration.	
6) Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) 1-28 are subject to restriction and/or e	election requirement	
Application Papers	rection requirement.	
9) The specification is objected to by the Examiner	•	
10) ☐ The drawing(s) filed on is/are: a) ☐ accep	ted or b) objected to by the	e Examiner.
Applicant may not request that any objection to the	e drawing(s) be held in abeyan	ce. See 37 CFR 1.85(a).
11)☐ The proposed drawing correction filed on	is: a) approved b) dis	approved by the Examiner.
If approved, corrected drawings are required in rep	ly to this Office action.	
12) The oath or declaration is objected to by the Exa	aminer.	
Pri rity under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. §	119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority documents	have been received.	
2. Certified copies of the priority documents	have been received in Ap	plication No
 Copies of the certified copies of the prior application from the International Bur See the attached detailed Office action for a list of the certified copies of the prior application. 	eau (PCT Rule 17.2(a)).	-
14) Acknowledgment is made of a claim for domestic	•	
a) The translation of the foreign language pro- 15) Acknowledgment is made of a claim for domesti	visional application has bee	en received.
Attachment(s)	- p	02
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Inf	Immary (PTO-413) Paper No(s) ormal Patent Application (PTO-152)

Application/Control Number: 10/051,956 Page 2

Art Unit: 1632

DETAILED ACTION

1. Claims 1-28 are pending.

Election/Restrictions

2. Restriction to one of the following inventions is required under 35 U.S.C.

121:

- Claims 1-13, drawn to a method of producing non-human mammal,
 classified in class 800, subclass 21.
- II. Claims 14-21, drawn to a method of producing an oocyte with reduced zona pellucida layer, classified in class 435, subclass 325.
- III. Claims 22-28, drawn to an oocyte with reduced zona pellucida layer, classified in class 435, subclass 325.
- 3. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not

Art Unit: 1632

commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

4. The inventions are distinct, each from the other because of the following reasons:

Inventions of the groups II and III are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the method comprises decreasing the thickness of the zona pellucida of a non-human mammalian oocyte by treating the oocyte with tyrode solution or changing pH or proteinase treatment. These treatments are used for cell washing and cell culture. The product, an oocyte with reduced zona pellucida can be produced by treating it with laser. Therefore, the inventions of the groups II and III are patentably distinct.

5. Inventions of the group I is patentably distinct from that of groups II and III because the invention of group I is drawn to a method of producing a non-human mammal, which will require different search in the patent and non-patent literature and is classified in a different class and subclass. Additionally, the search for the inventions will not be co-extensive.

Application/Control Number: 10/051,956 Page 4

Art Unit: 1632

6. Because these inventions are distinct for the reasons given above, have acquired a separate status in the art shown by their different classification and their recognized divergent subject matter, and because each invention requires a separate, non-coextensive search, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ram R. Shukla whose telephone number is (703) 305-1677. The examiner can normally be reached on Monday through Friday from 7:30 am to 4:00 p.m. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached on (703) 305-4051. The fax phone number for TC 1600 is (703) 703-872-9306. Any inquiry of a general nature, formal matters or relating to the status of this application or proceeding should be directed to the William Phillips whose telephone number is (703) 305-3413.

Ram R. Shukla, Ph.D. Primary Examiner

Art Unit 1632